Companies /Healthcare

Ocugen Inc

NASDAQ: OCGN Biotechnology
$1.05
▲ $0.03 (+2.44%) today
Markets open · 11:49am ET

Q1 2025 Earnings

Reported May 9, 2025, 9:45am ET · SEC source
$-0.05
Beat +16.67%
EPS · est. $-0.06
$1.5M
Beat +0.00%
Revenue · est. $0
+66.6%
Beating market
OCGN vs S&P since report
4 quarters
Consecutive EPS misses

Market Reaction

% change · around the report
−9%−6%−3%0May 9May 9report 9:45am ETearnings−0.3%−7.4%
−9%−6%−3%0May 9May 9earnings−0.3%−7.4%
OCGN −7.4%S&P 500 −0.3%
−9%−6%−3%0May 9May 9report 9:45am ETearnings−0.5%−7.4%
−9%−6%−3%0May 9May 9earnings−0.5%−7.4%
OCGN −7.4%NASDAQ −0.5%
−7%0+7%+14%May 8May 16report 9:45am ETearnings+3.9%+6.1%
−7%0+7%+14%May 8May 16earnings+3.9%+6.1%
OCGN +6.1%S&P 500 +3.9%
−7%0+7%+14%May 8May 16report 9:45am ETearnings+5.0%+6.1%
−7%0+7%+14%May 8May 16earnings+5.0%+6.1%
OCGN +6.1%NASDAQ +5.0%
−2.76%
Day of report
+4.48%
Next session
+13.13%
One week
+73.13%
30 days

S&P 500 over the same 30 days: +6.56%.

Did OCGN Beat Earnings? Q1 2025 Results

Ocugen posted a narrower-than-expected loss in Q1 2025, offering a modest bright spot for a clinical-stage company navigating a demanding multi-program pipeline. The gene therapy developer reported an EPS loss of $0.05, beating the consensus estimate of $0.06 by 16.67%, while collaborative arrangement revenue climbed 46.1% year-over-year to $1.48 million, clearing a bar analysts had set at zero. The better-than-feared bottom line, however, masked a widening net loss of $15.35 million, driven by a surge in R&D spending to $9.53 million as the company pressed forward on three modifier gene therapy programs simultaneously. Cash declined to $38.10 million from $58.80 million at year-end, with management projecting the runway extends into Q1 2026, underscoring the urgency of securing additional financing or partnerships. Looking ahead, Ocugen is targeting BLA/MAA filings for its lead retinitis pigmentosa program OCU400 by mid-2026, with the OCU410ST pivotal trial for Stargardt disease set to initiate by mid-2025, keeping the company's three-year filing ambitions intact.

Key Takeaways
  • Increased R&D spending driven by advancing multiple clinical programs through Phase 2/3 and Phase 3 trials
  • Collaborative arrangement revenue increased to $1.5 million from $1.0 million year-over-year

“All three of our novel modifier gene therapies are advancing through the clinic and we are on track to meet our goal of three Biologics License Application (BLA)/Marketing Authorization Application (MAA) filings in the next three years.”

Ocugen CEO, on the earnings call

Forward Guidance & Outlook

Ocugen expects its cash and restricted cash runway to extend into Q1 2026. The company targets BLA/MAA filings for OCU400 by mid-2026, plans to initiate the OCU410ST Phase 2/3 pivotal trial by mid-2025 with a target BLA filing in 2027, and aims to complete the OCU200 Phase 1 trial in H2 2025. The company aims for three BLA/MAA filings across its modifier gene therapy programs within the next three years. NeoCart Phase 3 initiation is contingent on adequate funding availability and/or a future partnership. NIAID intends to initiate a Phase 1 clinical trial for OCU500 in Q2 2025.

OCGN YoY Financials

Q1 2025 vs Q1 2024 · SEC filings Q1 2024 Q1 2025
$-21,000,000$-14,000,000$-7,000,000$0$1.0M$1.5MRevenue$-17,836,408$-14,501,000Operating Income$-21,537,814$-15,350,000Net Income
$-21,000,000$-14,000,000$-7,000,000$0RevenueOperating IncomeNet Income

OCGN Revenue by Segment

Collaborative Arrangement Revenue

Figures from SEC filings and company reports. Not investment advice.